Calcium supplementation during pregnancy and maternal and offspring bone health: a systematic review and meta-analysis

Kati Tihtonen, Päivi Korhonen, Jaana Isojärvi, Riitta Ojala, Ulla Ashorn, Per Ashorn, and Outi Tammela

1Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland. 2Faculty of Medicine and Health Technology, Center for Child, Adolescent, and Maternal Health Research, Tampere University, Tampere, Finland. 3Department of Pediatrics, Tampere University Hospital, Tampere, Finland. 4Library, Tampere University, Tampere, Finland

Address for correspondence: Kati Tihtonen, Department of Obstetrics and Gynecology, Tampere University Hospital, PL 2000, 33521 Tampere, Finland. kati.tihtonen@pshp.fi

Insufficient calcium intake during pregnancy may lead to maternal bone resorption and lower bone density of offspring. We evaluated the impact of supplementary calcium with or without vitamin D during pregnancy on maternal and offspring bone mineral density (BMD) and teeth firmness of the offspring. Randomized controlled trials (RCTs) were searched systematically in 11 databases. Two researchers independently screened the titles and abstracts of 3555 records and the full texts of 31 records to examine eligibility. The search yielded seven RCTs (11 reports, \( n = 1566 \)). No advantage of calcium supplementation was found on maternal BMD after delivery or during breastfeeding, or on offspring BMD, even when dietary calcium intake was low. The results were neither modified by the dose of calcium nor concomitant vitamin D administration. A suspicion of some long-term harm of the intervention on maternal BMD and growth of female offspring was raised based on the data. One study suggested some benefit of high-dose calcium supplementation on offspring teeth firmness at 12 years old. A low number of the studies and abundant missing data reduced the quality of the findings. The impact of calcium supplementation on maternal and offspring bone health was deemed unknown because of inconclusive research results.

Keywords: pregnancy; calcium supplementation; vitamin D; offspring; bone mineral density

Introduction

Pregnancy and breastfeeding could compromise maternal bones due to increased need of calcium to allow mineralization of the skeleton of the growing fetus and the infant. During pregnancy, the absorption of calcium from the intestine is increased, correlating directly with maternal calcium intake. Calcium is actively transported to the fetus by the placenta. If calcium intake is low, calcium release from the maternal bones becomes prevalent toward the end of the pregnancy. This may lead to low maternal bone mineral density (BMD), risk of delayed bone maturation of the newborn, and decreased BMD or teeth firmness of the offspring in later life.

Calcium intake is lower than recommended in large areas of the world. In such areas, supplementation is recommended during pregnancy to avoid preeclampsia. Theoretically, such supplementation might be expected to also positively affect maternal or child bone health. The aim of this systematic review was to synthesize the available data from randomized controlled trials (RCTs) to establish the impact of calcium supplementation, alone or with vitamin D during pregnancy, on maternal

doi: 10.1111/nyas.14705

Ann. N.Y. Acad. Sci. 1509 (2022) 23–36 © 2021 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals LLC on behalf of New York Academy of Sciences

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
and offspring bone health and teeth firmness. The goal was also to investigate whether the impact of calcium is dependent on supplementary dose or maternal baseline dietary calcium intake.

**Methods**

The study protocol was planned according to the Preferred Reporting Items For Systematic Review And Meta-Analysis Protocols (PRISMA-P)⁴ and registered in PROSPERO on April 28, 2020 (CRD42020173348).

We searched for RCTs, including cluster-randomized studies, on pregnant women and their offspring. The primary target settings were South Asia and Sub-Saharan Africa, but other settings were not excluded. Interventions included supplementary calcium alone or with vitamin D during pregnancy, starting at 35 gestational weeks at the latest and stopping at delivery. We accepted studies using elemental calcium doses up to the maximum of 2000 mg/day and vitamin D (vitamin D, cholecalciferol, or ergocholecalciferol) doses up to the maximum of 4000 IU (100 µg)/day. Studies on food fortification were excluded. We included studies with control groups using placebo, no treatment, standard care, or regular diet.

The originally chosen follow-up periods for maternal bone health were during pregnancy and up to 2 years after delivery, and in the case of offspring, from birth up to the age of 7 years. Since the number of studies was scarce, eventually even longer follow-up periods were accepted. Primary outcomes of interest for maternal bone health were BMD, bone area (BA), and bone mineral content (BMC) measured in the whole body, lumbar spine, hip, radius, or tibia. Primary outcomes of interest for offspring’s bone health were BMD, BMC, BA, bone mass, and bone mineral accretion measured in the whole body, lumbar spine, hip, radius, or tibia, and the incidence of rickets. Both maternal and offspring secondary outcomes were teeth firmness, with the variables including dental caries, decayed teeth, missing teeth, filled teeth, erupted permanent second molars, enamel hypoplasia, and teeth mineral density. Mixed dentition was studied only in the offspring and bone fractures only in the mother.

**Search strategy**

An experienced information specialist (J.I.) developed the literature search strategy. Searches were conducted in MEDLINE (via OvidSP), Cochrane Central Register of Controlled Trials (CENTRAL, via Wiley Cochrane Library), CINAHL Complete (via EbscoHOST), Scopus, Science Citation Index (via Web of Science), Social Science Citation Index (via Web of Science), Conference Proceedings Citation Index - Science (via Web of Science), Conference Proceedings Citation Index - Social Science & Humanities (via Web of Science), ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (WHO ICTRP), and PROSPERO.

Strategies for identifying relevant reports of RCTs comprised both database-specific subject headings (e.g., Medical Subject Headings (MeSH)) and terms that are likely to appear in study titles and abstracts (Supplementary File 1, online only). We applied published search filters to inform the strategies in MEDLINE⁵ and CINAHL.⁶

We did not include animal studies. Publication types unlikely to provide relevant information, such as editorials and news, were excluded where possible. No other limits were applied. We screened the reference lists of relevant reviews for any additional applicable studies. No additional studies were identified.

Searches were undertaken on September 7, 2020. We loaded the results into EndNote (version X9.3, Clarivate Analytics) for deduplication.

**Study selection**

Two authors (K.T. and P.K.) independently screened the titles and abstracts of the records, as well as full texts of studies eligible for outcome analysis using Covidence (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia), online software for streamlining systematic review processes. Disagreements were solved through discussion. Reasons for exclusion of the studies during full-text screening were recorded. Neither of the review authors was blinded to the journal titles, study authors, or institutions. A PRISMA flow chart for the screening process was generated.

Next, two authors (K.T. and P.K.) independently extracted data using Covidence, solving disagreements by discussion. The extracted data included (1) author, publication year, country, and area; (2) study design; (3) characteristics of the study population and controls (number of randomized and analyzed, age, parity, and baseline dietary intake for calcium); (4) description and duration of
intervention; (5) outcome measurements; and (6) effect measures, if applicable.

**Risk of bias**
Two authors (K.T. and P.K.) independently evaluated the risk of bias by using the Cochrane risk-of-bias tool for randomized trials in Covidence with the following domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data (attrition bias), selective outcome reporting, and other bias. Each domain was graded as having low, unclear, or high risk of bias, with disagreements solved by discussion. Studies with some concern as well as lack of information on the risk of bias were graded as having unclear risk of bias. Follow-up reports on the same original study population were merged for the evaluation of risk of bias. For follow-up studies or subsets of trials originally designed to evaluate the impact of calcium supplementation on hypertensive disorders in pregnancy, two risk-of-bias domains (sequence generation and allocation concealment) were assessed from the original trials. When appropriate, domains were assessed for different outcomes separately.

**Data analysis**
The data that were extracted using Covidence were exported to RevMan 5.4 software (the Cochrane Collaboration, 2020) for further analyses. Continuous outcomes were analyzed using mean differences with 95% CI. We performed forest plot analyses for outcome parameters with the same measured bone site and approximately same time point from at least two different studies. We used fixed-effect meta-analysis for combining information where it was reasonable to assume that studies were estimating the same underlying treatment effect. The heterogeneity of the studies in the meta-analysis was assessed using I², a Chi-squared test, and Tau². In case of heterogeneity across the studies (I² > 50%, Tau² > 0 or P < 0.10), we used random-effects meta-analysis.

We planned to do subgroup analyses according to the dose of calcium (low dose: less than 1000 mg/day; high dose: 1000 mg or more/day), calcium supplementation alone and with vitamin D, women or populations with low dietary calcium intake (as defined by trial authors, or if not defined, mean daily intake less than 900 mg), geographical areas (Sub-Saharan Africa and South Asia), teenagers and multiparas, if appropriate data were available.

**Interpretation of evidence**
We interpreted the available evidence according to the coding as presented in Table 1. The categories included positive effect, possible positive effect, no positive effect, and unknown effect because of insufficient or inconclusive published research.

**Results**

**Study selection**
Literature searches retrieved 5027 records in total, and 3555 records remained for assessment of titles and abstracts after deduplication. Out of these, 3524 records were excluded, and full text screening of the remaining 31 references for eligibility was performed. Altogether seven RCTs (11 reports) involving 1566 participants (n = 413 women with maternal outcome data and n = 1153 with offspring outcome data) were included in this review (Fig. 1).

**Study characteristics**
The included studies were published between 1978 and 2019 and seven of the reports were published in 2010 or later. From the seven identified studies (Table 2), three were trials originally examining the prevention of hypertensive disorders during pregnancy by calcium supplementation and including more than 6000 participants. Four studies, including 531 participating mothers, were originally designed to establish the effect of calcium supplementation during pregnancy on bone density. Two studies were conducted in the United States, while the remaining were from middle- or low-income countries, that is, India, China, the Gambia, Brazil, and Argentina. One study was conducted specifically in pregnant women in the poor socioeconomic segment and one in adolescent women; otherwise, participants were unselected pregnant women in defined areas or populations. The numbers of participants ranged between 64 and 447 per reports (Table 2). The mean maternal daily nutritional calcium intake was under the recommended daily allowance (<900 mg) in three studies, within recommendation in one, and in three studies, it was not clearly stated.

Three studies used low-dose calcium (<1000 mg) and four studies used high-dose calcium (≥1000 mg). Two studies combined vitamin D (200–400 IU = 5–10 µg) with low-dose calcium.
supplementation. Intervention started before the third trimester of pregnancy and ended at parturition in all studies (Table 2). Maternal compliance was stated in 6 out of 11 reports. The compliances ranged between from 62%\(^17\) to 85%\(^{14,18}\) to nearly 100%.\(^{19–21}\)

Six studies reported maternal or offspring bone outcomes, and one evaluated offspring oral health. No studies reported rickets, bone fractures, or maternal oral health as outcomes. Maternal bone outcomes were measured from peripheral bones (metacarpal, phalanx, radius, or tibia) in four studies, and two studies included whole body, lumbar spine, total hip, or femoral neck. Three studies included follow-up during lactation. There were no significant differences in the percentages of women exclusively or predominantly breastfeeding between the study groups when data were available.\(^{12,14,20,21}\) For offspring, peripheral bones (radius, ulna, tibia, or fibula) were measured in three studies, and whole body, lumbar spine, or total hip in four studies. Three studies included a follow-up period after the neonatal period, up to 12 years of age. The child’s calcium or vitamin D intake was not specified in these reports.\(^{18,19,22}\) One study in Argentina evaluated offspring oral health at 12 years of age.\(^{16}\) The first measurement point for bone outcomes after pregnancy and the follow-up period varied across the studies, as well as techniques to estimate bone mineralization (Table 2).

### Risk of bias

Five out of seven studies were assessed as having a low risk of bias in at least five of seven evaluated domains. And two studies were graded as having unclear or high risk of bias in over half of the evaluated domains (Fig. 2).

The risk of bias was estimated to be low considering random sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessment domains in five out of seven studies (Fig. 2). In three studies, there were no clear statements of allocation concealment\(^{12,14}\) or random sequence generation,\(^{17}\) and in one study, the intervention was not blinded,\(^{12}\) leading to a high risk of bias. A study conducted in China was considered to have high risk of attrition bias, since after randomization, 44% of women randomized to intervention group were able to shift to the placebo group.\(^{13}\)

One of the major concerns was incomplete outcome data. The amount of missing data depended

---

**Table 1. Coding for the interpretation of the available evidence**

| Standardized statement                                                                 | Situations included                                                                 |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| **Unknown effect: insufficient published research on the intervention’s effect on the outcome** | No RCTs, one low-quality RCT with any result, or One moderate-to-high quality RCT where the 95% CI of the RR includes 1, or Only narrative reporting |
| **Unknown effect: inconclusive published research on the intervention’s effect on the outcome** | At least two RCTs, 95% CI of the point estimate for an RR broadly spans both sides of 1 (ranges from \(<0.5\) to \(>2\)) |
| **Positive effect: the intervention likely reduces the risk of the adverse outcome**    | At least two moderate-to-high quality RCTs included in a meta-analysis or IPD meta-analysis, 95% CI of the point estimate of the RR is entirely less than 1 |
| **Possible positive effect: the intervention may reduce the risk of the adverse outcome** | At least two RCTs included in a meta-analysis or IPD meta-analysis, 95% CI of the point estimate of the RR is entirely less than 1, but there is concern about the quality of the data, or At least two moderate-to-high quality RCTs included in a meta-analysis or IPD meta-analysis, 95% CI of the point estimate of the RR includes 1 but the 90% CI of the point estimate of the RR is entirely less than 1, or One moderate-to-high quality RCT, 95% CI of the point estimate of the RR is entirely less than 1 |
| **No positive effect: the intervention is unlikely to reduce the risk of the adverse outcome** | Other situations, including meta-analysis results suggestive of harm |

CI, confidence interval; IPD, individual participant data; RCT, randomized controlled trial; RR, relative risk.
Table 2. Characteristics of the included randomized controlled studies

| Original reference Country | Number of originally randomized women (Ca/placebo), population | Baseline maternal calcium intake mg/day (mean ± SD), Ca/placebo | Daily dose of calcium and vitamin D | Intervention timepoints and outcome | Original primary outcome | Maternal outcome reference |
|---------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------|----------------------------------|--------------------------|---------------------------|
| Raman et al.12, India 273, study groups not specified, poor socioeconomic segment of the population | 593/601, selected hospitals | NA | Group 1: 300 mg Ca, Group 2: 600 mg Ca, Group 3: placebo | 18–22 weeks of gestation | Maternal and neonatal bone density in peripheral bones | Raman et al.12, Wang et al.13, Goldberg et al.14, Cullers et al.15 | | | |
| Belizán et al.13, Argentina | 2295/2294, nulliparous | 646 ± 396/642 ± 448 | 2000 mg Ca | 20 weeks of gestation | Incidence of hypertensive disorders of pregnancy | Wang et al.13, Diogenes et al.14, Jarjou et al.21, Jarjou et al.22, Cullers et al.15 | | | |
| Levine et al.10, The United States | 55/55, selected hospital area | 1113 ± 691/1135 ± 675 | 300 mg Ca | 13–21 weeks of gestation | Incidence of preeclampsia | Wang et al.13, Diogenes et al.14, Jarjou et al.21, Jarjou et al.22, Cullers et al.15 | | | |
| Wang et al.13, China | 43/41, adolescents (13–19 years old) in select hospital area | NA (600–800 in average in China) | 600 mg Ca | 26 weeks of gestation | Maternal radial BMD and neonatal BMD of tibia and fibula | Wang et al.13, Diogenes et al.14, Jarjou et al.21, Jarjou et al.22, Cullers et al.15 | | | |
| Diogenes et al.14, Brazil | 330/332, rural villages | 500 ± 276/743 ± 457 | 2000 mg Ca | 20 weeks of gestation | Maternal systolic and diastolic blood pressure at 36 weeks of gestation | Wang et al.13, Diogenes et al.14, Jarjou et al.21, Jarjou et al.22, Cullers et al.15 | | | |
| Goldberg et al.14, The Gambia | 16 ± 2 weeks of gestation | 355 ± 190 (whole study population) | 1500 mg Ca | Maternal and neonatal bone mass, fetal growth | Peripheral cortical and trabecular bone changes during a reproductive cycle | Wang et al.13, Diogenes et al.14, Jarjou et al.21, Jarjou et al.22, Cullers et al.15 | | | |
| Cullers et al.15, The United States | 708 ± 380/757 ± 323 | | 1000 mg Ca | | | | | | |

Offspring outcome

| Original reference Country | Time points and measured bone sites (number of women data obtained Ca/placebo) | Offspring outcome reference | Neonatal, radius, ulna, tibia, and fibula, (group 1:24, group 2:25, and group 3:38) | 12 years old, primary and permanent teeth (98/97) | 5 weeks pp (26/21), 20 weeks pp (26/21), total body, lumbar spine, total hip, and femoral neck | Raman et al.24, Bergel et al.25, Koo et al.27, Wang et al.13, Diogenes et al.14, Jarjou et al.23, Jarjou et al.24, Ward et al. (2017)22 | | | |
| | | | | | | 8–12 years old, whole body, lumbar spine, and total hip | | | |
| | | | | | | 27 | | | |

Offspring outcome

| Technique | Clinical examination | DXA | SPA | DXA | DXA | pQCT |
|-----------|---------------------|-----|-----|-----|-----|------|
| X-ray     | Clinical examination | DXA | SPA | DXA | DXA | pQCT |

NPNL indicates in the study by Jarjou et al.21 that the same women as at 52 weeks pp were invited for follow-up when neither pregnant nor lactating for >3 months. F52 indicates in the study by Jarjou et al.23 that the same women as at 52 weeks pp were invited for follow-up in a future lactation.

NA, not available; gw, gestational weeks; pp, postpartum; DXA, dual-energy X-ray absorptiometry; SPA, single-photon absorptiometry; pQCT, peripheral quantitative computed tomography.
Pregnancy calcium supplementation and bone health

Tihtonen et al.

Figure 1. Selection of the randomized controlled trials to the review. Figure is modified from Ref. 26.

Records identified from:
- MEDLINE (n = 441)
- CENTRAL (n = 1549)
- CRAN (n = 40)
- SCOP (n = 1123)
- SIGA (n = 51)
- COPCIS (n = 5)
- CPICIS-ISH (n = 4)
- ClinicalTrials.gov (n = 25)
- WHO ICTRP (n = 112)
- Prospero (n = 77)

Records removed before screening:
- Duplicate records removed (n = 1472)
- Records marked as ineligible by automation tools (n = 0)
- Records removed for other reasons (n = 0)

Records screened (n = 3055)

Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 31)

Studies included in review (n = 7)
- Reports of included studies (n = 11)

Records excluded (n = 3524)

Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 0)

Records identified from:
- Reference lists of reviews (n = 0)

Records identified from:
- Other methods (n = 0)

Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 0)

Studies included in review (n = 7)

Reports of included studies (n = 11)

Identification of studies via databases and registers

Identification of studies via other methods

Identification

Screening

Included

on the technique used and follow-up periods, but it was high in nearly all reports: 68%,12 17–30%,15 48–66%,21 32%,22 58–65%,19 44%,14 33%,18 and 44%.13 Furthermore, statements of sample size calculations were found in only a few reports.14,15,19

The risk of selective reporting bias was estimated to be low in six studies and unclear for one study13 since the statements on primary and secondary outcomes were missing. In the studies having the longest follow-up periods, there was a lack of data on potentially confounding or effect-modifying factors, such as nutritional intake, economic and educational factors, or physical activity, which may have an impact on outcomes of bone and oral health; therefore, the risk of bias was estimated to be unclear.16,21,22

Maternal bone outcomes

Bone health during pregnancy. BMD during pregnancy was evaluated in three studies (n = 447 randomized women; Table 3).12,13,15 Two studies from India and China used low-dose (either 300 or 600 mg) calcium supplementation in women with low calcium intake; the latter combined calcium supplementation with vitamin D. One study conducted in the United States used high-dose calcium supplementation (1000 mg) in women with low calcium intake. All studies included high risk of bias—especially due to missing data.

In the high-dose calcium supplementation study, there were no differences between the study groups in volumetric BMDs (vBMDs) in radial and tibial distal and proximal sites.15 In the low-dose calcium supplementation studies, insignificant differences were found in most measured bone sites, except radial13 and one metacarpal (in the highest supplement dose, i.e., 600 mg).12 BMDs were found to be significantly higher in the intervention group during pregnancy or around delivery.

Bone health within weeks after delivery. Two studies on a total of 209 randomized women evaluated BMDs within weeks after delivery (Table 3). A study from Brazil used low-dose calcium (600 mg) with vitamin D14 and another from the Gambia used high-dose calcium supplementation (1500 mg) in women with low calcium intake.20 The estimated risk of bias due to missing data ranged from high to unclear in these studies.

No significant differences were found in BMDs of the whole body, lumbar spine, or femoral
Meanwhile, BMDs in total hip and femoral shaft were found to be significantly lower in the intervention group in the Gambian study. No significant differences were found in radial BMDs.

**Bone health during breastfeeding or later.**

Three studies on a total of 273 randomized women estimated the impact of maternal calcium supplementation on her BMD during breastfeeding (Table 3). Baseline maternal calcium intake was lower than recommended in all the study populations. The dose of calcium supplementation was low with vitamin D in the Brazilian study and high in studies conducted in the United States and the Gambia. All of these studies included unclear
Table 3. The effect of calcium supplementation during pregnancy on maternal bone health, in comparison with placebo

| Study         | Time point | Bone site                  | Mid- to late-term pregnancy to delivery | Mid- to late-term pregnancy to delivery |
|---------------|------------|----------------------------|----------------------------------------|----------------------------------------|
| Tamminen et al., 2004 | 5 weeks pp | Whole body                 | 20 weeks pp                            | 2 weeks pp                             |
| Wang et al., 2004    | 52 weeks pp | Whole body                 | NPNL                                    | F2                                      |
| Jarnis et al., 2004  | 52 weeks pp | Whole body                 |                                        |                                        |
| Callers et al., 2004 | 52 weeks pp | Whole body                 |                                        |                                        |

NPNL indicates the study by Jarnis et al., 2004, that the same women as at 52 weeks pp were invited for follow-up when neither pregnant nor lactating for > 3 months. F52 indicates the study by Jarnis et al., 2004, that the same women as at 52 weeks pp were invited for follow-up in a future lactation.

NS, no significant differences between the study groups; ↑, significantly higher in the intervention group compared with the placebo, P ≤ 0.05; ↓, significantly lower in the intervention group compared with the placebo, P ≤ 0.05.

1 Bone density was assessed from a distal metaphyseal site of the tibia or radius.

2 Bone density was assessed from a proximal diaphysis site of the tibia or radius.

3 No difference at 12 months after delivery, but statistically significant group × time interaction effects were noticed from baseline to 12 months pp (visit 5) for two variables (radial diaphyseal total BMD: P = 0.029; tibial diaphyseal cortical BMD: P = 0.015).

BMC, bone mineral content (g); BA, bone area (cm²); cor, cortical; pp, postpartum; tot, total; trab, trabecular; (v)BMD, (volumetric) bone mineral density (g/cm² or g/cm³).

or high risk of bias due to incomplete outcome data.

Two studies found no statistically significant differences in BMDs of the whole body, lumbar spine, total hip, and femoral neck, or vBMDs of radius and tibia at 4 months to 1 year after delivery. However, in both of these studies, some positive effect of intervention was shown as a slower rate of losing BMD during follow-up in the intervention group. In the Brazilian study, significantly less femoral neck BMD loss was observed in the calcium supplementation group between 5 and 20 weeks after delivery. Similarly, the decrease of bone content from 36 gestational weeks to 12 months after delivery in total vBMD at radial proximal diaphyseal as well as in cortical vBMD at the tibial proximal diaphyseal site was less in the intervention group.
Maternal whole body BMD at 2 weeks and 5 weeks after delivery

| Study or Subgroup | calcium (+vitamin D) | placebo | Total | Mean Difference | Mean Difference IV, Random, 95% CI |
|------------------|----------------------|---------|-------|----------------|----------------------------------|
| Diogenes 2013    | 1.078 ± 0.129        | 1.029 ± 0.088 | 21   | 36.1%          | 0.05 [-0.01, 0.11] |
| Ward 2017       | 1.108 ± 0.081        | 1.057 ± 0.057 | 27   | 63.9%          | 0.00 [-0.03, 0.03] |
| Total (95% CI)   |                      |         | 48   |                | 0.02 [-0.03, 0.06] |

Heterogeneity: Tau² = 0.00, Chi² = 2.07, df = 1 (P = 0.15), I² = 99%
Test for overall effect Z = 1.75 (P = 0.08)

Maternal lumbar spine BMD at 2 weeks and 5 weeks after delivery

| Study or Subgroup | calcium (+vitamin D) | placebo | Total | Mean Difference | Mean Difference IV, Random, 95% CI |
|------------------|----------------------|---------|-------|----------------|----------------------------------|
| Diogenes 2013    | 1.098 ± 0.172        | 1.033 ± 0.114 | 21   | 41.1%          | 0.07 [-0.01, 0.15] |
| Ward 2017       | 1.005 ± 0.101        | 1.066 ± 0.112 | 27   | 59.9%          | -0.00 [-0.06, 0.06] |
| Total (95% CI)   |                      |         | 48   |                | 0.03 [-0.04, 0.09] |

Heterogeneity: Tau² = 0.00, Chi² = 1.79, df = 1 (P = 0.19), I² = 34%
Test for overall effect Z = 0.91 (P = 0.36)

Maternal total hip BMD at 2 weeks and 5 weeks after delivery

| Study or Subgroup | calcium (+vitamin D) | placebo | Total | Mean Difference | Mean Difference IV, Fixed, 95% CI |
|------------------|----------------------|---------|-------|----------------|----------------------------------|
| Diogenes 2013    | 1.052 ± 0.199        | 0.977 ± 0.115 | 21   | 36.6%          | 0.08 [-0.01, 0.16] |
| Ward 2017       | 0.999 ± 0.106        | 1.087 ± 0.117 | 23   | 63.4%          | -0.09 [-0.15, -0.02] |
| Total (95% CI)   |                      |         | 46   |                | -0.03 [-0.08, 0.02] |

Heterogeneity: Chi² = 8.41, df = 1 (P = 0.004), I² = 88%
Test for overall effect Z = 1.95 (P = 0.30)

Maternal femoral neck BMD at 2 weeks and 5 weeks after delivery

| Study or Subgroup | calcium (+vitamin D) | placebo | Total | Mean Difference | Mean Difference IV, Fixed, 95% CI |
|------------------|----------------------|---------|-------|----------------|----------------------------------|
| Diogenes 2013    | 1.081 ± 0.186        | 1.014 ± 0.125 | 21   | 46.7%          | 0.05 [-0.04, 0.13] |
| Ward 2017       | 0.988 ± 0.112        | 1.042 ± 0.107 | 23   | 53.3%          | -0.05 [-0.12, 0.01] |
| Total (95% CI)   |                      |         | 46   |                | -0.01 [-0.11, 0.09] |

Heterogeneity: Tau² = 0.00, Chi² = 3.84, df = 1 (P = 0.05), I² = 71%
Test for overall effect Z = 1.14 (P = 0.26)

Offspring whole body BMD within one week, at 2 weeks and 5 weeks after delivery

| Study or Subgroup | Calcium supplementation | Total Mean Difference | Mean Difference IV, Fixed, 95% CI |
|------------------|-------------------------|-----------------------|----------------------------------|
| Diogenes 2013    | 0.370 ± 0.06            | 30 ± 0.393 ± 0.056    | 30 ± 0.00 [-0.02, -0.04, 0.01] |
| Koo 1999        | 0.216 ± 0.002           | 128 ± 0.212 ± 0.002   | 128 ± 0.98 [0.00, 0.00]          |
| Ward 2017       | 0.487 ± 0.018           | 20 ± 0.48 ± 0.023     | 24 ± 0.24 [0.01, 0.02]           |
| Total (95% CI)   |                        |                      | 178 ± 0.00 [0.00, 0.00]          |

Heterogeneity: Chi² = 1.84, df = 2 (P = 0.40), I² = 0%
Test for overall effect Z = 16.01 (P = 0.000e01)

Figure 3. Meta-analysis and forest plots of the studies of maternal and offspring bone mineral density after delivery. The reference citations for the indicated studies are Diogenes 2013 (Ref. 14), Ward 2017 (Ref. 22), and Koo 1999 (Ref. 17). * Owing to the merging of studies, Ward 2017 refers to the report by Jarjou 2006 (Ref. 19) when considering offspring outcome and the report by Jarjou 2013 (Ref. 21) considering maternal outcomes. [Correction added on December 06, 2021, after first online publication: In Figure 3, placement of the labels “favors placebo” and “favors calcium” was corrected.]

Femoral sites were significantly lower in the calcium supplementation group at 1 year after delivery.20 The significant difference persisted in two long follow-up periods: nonpregnant mothers ≥3 months after the stop of lactation, and in mothers at 52 weeks after delivery in a subsequent lactation.21 A meta-analysis that included two studies on maternal BMDs in the whole body, lumbar spine, total hip, and femoral neck at 2–5 weeks after...
Table 4. The effect of calcium supplementation during pregnancy on offspring bone health, in comparison with placebo

| Study                | Time point          | Raman et al. 12 | Wang et al. 13 | Koo et al. 17 | Diogenes et al. 18 | Jarjou et al. 19 | Ward et al. 22 |
|----------------------|---------------------|-----------------|---------------|---------------|-------------------|-----------------|--------------|
|                      |                     | Neonatal        | Neobnateal    | Within the first week | 5 weeks | 2 weeks | 13 weeks | 52 weeks | 8–12 years |
| Whole body           |                     | BMD NS          | BMD NS        | BMD NS        | BMD NS            | BMD NS         | BMD NS      | BMD NS    | BMD NS     |
| Lumbar spine         |                     | BMD NS          | BA NS         | BA NS         | BA NS             | BA NS          | BA NS       | BA NS     | BA NS      |
| Total hip            |                     | BMD NS          | BA NS         | BA NS         | BA NS             | BA NS          | BA NS       | BA NS     | BA NS      |
| Midshaft radius/ulna/tibia/fibula | BMD ↑* | BMD ↑ | BMD NS | BMD NS | BMD NS | BMD NS | to MBD | NS M | NS M |

NS, no significant differences between the study groups; ↑, significantly higher compared with the placebo, P ≤ 0.05; ↓, significantly lower compared with the placebo, P ≤ 0.05.

* Considering both studied calcium supplementation groups (300 and 600 mg).

† Significantly slower increase in BMC and BA between the age of 2 and 52 weeks in the calcium supplementation group.

‡ In the study by Ward et al., two models were constructed to test for sex-supplement effects on the growth of the children at 8–12 years. The first model included length at 52 weeks, current age, sex (M/F), maternal supplement group (Ca/P), and a sex-supplement group interaction.

§ In the study by Ward et al., two models were constructed to test for sex-supplement effects on the growth of the children at 8–12 years. The second model was based on the first but adjusted the bone and body composition data for current body size, using height and weight for bone variables and height for lean and fat masses.

BA, bone area (cm²); BMC, bone mineral content (g); BMD, bone mass density (g/cm²); F, female; M, male; tot vBMD, total volumetric BMD (g/cm³).

delivery did not favor either group. The heterogeneity was substantial (I² > 30%) (Fig. 3).

The impact of maternal calcium supplementation during pregnancy on the mother’s bone health during pregnancy, after delivery, and during and after lactation was deemed unknown because of inconclusive research results.

**Offspring bone outcomes**

**Bone health during the neonatal period.** There were three studies including a total of 453 infants on bone outcomes during the neonatal period (Table 4). One study was from India on 87 mothers with either 300 or 600 mg/day calcium doses or placebo, one study was from China on 110 mothers with 300 mg/day calcium combined with vitamin D in the intervention group, and one was a substudy from the trial on preeclampsia prevention in the United States. The American study included 256 mothers with high dose (2000 mg/day) calcium supplementation as an intervention in women with sufficient calcium intake. All these studies were assessed as having unclear or high risk of bias.

No intergroup differences were found in the American study, either in whole-body or lumbar spine BMD. In a further analysis, the study population was divided according to maternal dietary calcium intake at baseline. Among neonates of mothers with calcium intake in the lowest quintile (mean = 411 mg/day, n = 51 infants), the calcium supplementation group had significantly higher mean whole-body BMC (64.1 g) compared with the placebo (55.7 g) group during the first week of life. No significant differences were found in other calcium intake quintiles. In two smaller studies with a high risk of bias, the BMDs of the infants were significantly higher in the supplementation groups in peripheral bones, that is, radius, ulna, tibia, and fibula.

**Bone health within weeks after birth.** Later, within weeks after birth, BMDs were established in two studies (Table 4), one from Brazil (56 offspring of 84 adolescent mothers using low-dose calcium with vitamin D versus placebo) and one from the Gambia (42–120 infants of 662 mothers using high-dose calcium versus placebo). Maternal baseline
calcium intake was low in both studies. Both studies included some risk of bias because of missing data.

No significant differences between the study groups were found in BMDs measured from the whole body\textsuperscript{17,19} or radius\textsuperscript{19} within 2–13 weeks after delivery. The finding was similar in whole-body and radial BMDs at the subsequent follow-up at 52 weeks after birth in the Gambian study.\textsuperscript{19} A further analysis suggested a slower rate of increase of whole-body BMC and BA, but not whole-body BMD, within the calcium supplement group, suggesting a slower velocity of bone growth at 52 weeks compared with the placebo group.\textsuperscript{19}

**Bone health in later childhood.** The longest follow-up study of 8–12 years was on 499 children from the Gambia,\textsuperscript{22} where the original maternal calcium dose had been 1500 mg/day (Table 4). There was unclear risk of bias in the category of other sources bias, since confounding factors, such as nutrition (especially dietary calcium intake), education, and income, which may influence the bone content outcomes in long-term follow-ups, were not stated.

From this analysis, comparisons were only reported separately for females and males. In females, the BMCs and BAs in the whole body, lumbar spine (BMC only), and total hip were lower in the intervention group compared with the controls, when adjusted for length at 1 year of age. Among females, the studied bones were also lighter and smaller (lower BMC and BA in the whole body, lumbar spine, and total hip) in the intervention group than the control group at 8–12 years of age. However, the difference became nonsignificant when the analysis was adjusted for the participants’ current body size (height and weight). No differences were found in peripheral bones (tibia) in any analyses.\textsuperscript{22}

A meta-analysis of offspring whole-body BMD measured within weeks after birth included three studies.\textsuperscript{17,18,19} It very marginally favored calcium supplementation (Fig. 3). [Correction added on December 06, 2021, after first online publication: The last sentence of this paragraph was corrected.]

The impact of maternal calcium supplementation during pregnancy on offspring bone health was deemed unknown because of inconclusive research results.

**Offspring dental health.** One trial from Argentina,\textsuperscript{16} where the high-dose calcium supplementation (2000 mg/day) or placebo was originally aimed to prevent hypertensive disorders in pregnancy (\(n = 1194\) women), conducted a follow-up study on offspring oral health. A total of 195 children at the age of 12 years were examined. The risk of bias was unclear in the category of other sources of bias, since differences in the study population characteristics, such as nutrition (especially calcium intake), social situation, or income, which potentially lead to bias, were not taken into account.

The numbers of children with at least one decayed, missing, or filled tooth in the permanent and primary teeth (DMFT/dmft) were significantly lower in the intervention group (\(n = 62\)) than the control group (\(n = 84\)) (63% versus 87%, \(P < 0.001\)). When these were estimated separately for the primary and permanent teeth, the significant difference remained only with permanent teeth (\(n = 59\) (60%) versus \(n = 79\) (81%), \(P < 0.001\)). The numbers of decayed, missing, or filled surfaces (DMFS/dmfs) were significantly lower in the calcium supplementation group compared with the placebo group (mean (SD) = 3.1 (4.1) versus 4.4 (4.1), \(P < 0.001\)). No differences were found in the numbers of children with erupted permanent second molars, with mixed dentition, or with enamel hypoplasia. Our interpretation of the data was that maternal calcium supplementation during pregnancy possibly improves dental health of the offspring during childhood.

**Discussion**

**Summary of main results**

**The effect of calcium supplementation during pregnancy on maternal bone health.** In our systematic review, we found inconclusive results for calcium supplementation on maternal BMD during mid- to late pregnancy and after the stop of the intervention within weeks after delivery.\textsuperscript{12–15,20} This was because of heterogeneity of the assessment methods, risks of bias, and partly the low quality of the studies. Also, meta-analyses on maternal BMDs up to 5 weeks postpartum did not favor either group. The effect of calcium supplementation was not enhanced either by a high dose of calcium or concomitant vitamin D.

Later, about 1 year after delivery and during lactation, one study\textsuperscript{20,21} found that the results of
the maternal skeletal assessments were worse in the calcium supplementation group compared with placebo. No improvement was found after the cessation of lactation and in a subsequent lactation.\textsuperscript{21}

**The effect of maternal calcium supplementation during pregnancy on offspring bone health.** Some better BMDs in the maternal calcium supplementation group compared with the controls during the early neonatal period were suggested in some studies.\textsuperscript{12,13} A meta-analysis of offspring BMD within weeks after birth very marginally favored calcium supplementation, but the summary of the follow-up study up to 1 year of age showed no significant advantage of the intervention on offspring bone health.\textsuperscript{19} The effect of calcium supplementation during pregnancy on the offspring BMDs was deemed to be unknown because of inconclusive research results. This was mainly because of high or unknown risk of bias due to incomplete outcome data. [Correction added on December 06, 2021, after first online publication: The second and third sentences of the previous version of this paragraph were corrected and combined into the second sentence of the current version of this paragraph.]

One study reported a slower bone growth velocity during the first year of life in the calcium supplementation group.\textsuperscript{19} In addition, a long-term follow-up study showed a sex-specific difference, that is, a slower growth and smaller skeleton size and composition at 8–12 years of age in female offspring of calcium-supplemented mothers.\textsuperscript{22}

Maternal high-dose calcium supplementation may possibly have a long-term positive effect on the teeth firmness of offspring.\textsuperscript{16}

**Completeness and applicability of evidence**

The amount of missing data was notable, being 68\% at the highest,\textsuperscript{12} and between 17\% and 30\% at the lowest.\textsuperscript{15} The primary objective of three of the included studies, involving the majority of study subjects in this review, was hypertensive disorders in pregnancy,\textsuperscript{9–11} while the smaller proportion of the subjects were from studies where maternal and/or offspring bone health was the primary outcome measure.\textsuperscript{12–15} Because the original study populations included participants from low-, middle-, and high-income countries, and with both low and sufficient maternal dietary calcium intakes, the applicability of the results cannot be specified for any particular populations, dietary patterns, or geographic areas.

**Quality of evidence**

The numbers of participants were small, that is, altogether less than a hundred participants in each group in the studies on maternal bone health.\textsuperscript{12–15,20,21} In the studies concerning offspring bone health, the numbers of participants ranged between 350 and 450, depending on the ages at assessment.\textsuperscript{12,13,17,18,21,22} Clear statements of allocation concealment or random sequence was missing in almost half of the studies,\textsuperscript{12,14,17} and the intervention was not blinded in one.\textsuperscript{12} The quality of one study was hampered by allowing a shift from the intervention group to the placebo after randomization and another due to an unclear selective reporting bias.\textsuperscript{13} Sample size calculations were appropriately specified in less than half of the reports.\textsuperscript{14,15,19}

Lack of data on effect-modifying factors, including dietary habits, nutrient and vitamin intakes, and physical activity, which may have an impact on bone and oral health, was a weakness, especially in the studies with longest follow-up periods.\textsuperscript{16,21,22}

**Potential biases in the review process**

The searches were thoroughly planned in close collaboration with an experienced information specialist who also performed the searches. Criteria of inclusion of studies were clearly defined. The members of the review team were not involved in any of the studies. The review process was performed according to the PRISMA-P. Post-hoc inclusions were defined and reported.

**Agreements and disagreements with other studies or reviews**

Although calcium supplementation during pregnancy has been shown to be beneficial in preventing preeclampsia,\textsuperscript{23,24} there was no clear evidence of any sustained benefit of the supplementation on maternal bone health. Instead, possible long-term adverse effects on maternal bone health after withdrawal of the supplementation are of concern. The investigators of the study from the Gambia proposed that pregnant women with low dietary calcium intake might have adaptive mechanisms for the maintenance of the bone mineralization. High-dose calcium supplementation during pregnancy might downregulate this adaptation for a prolonged time. After withdrawal of the supplementation,
this might lead to reduced bone density during lactation, after weaning from breastfeeding, and in a subsequent lactation.\textsuperscript{20,21} More studies are needed to confirm this finding.

A recently published systematic review assessed whether calcium supplementation has a beneficial effect on maternal BMD during lactation.\textsuperscript{25} Their search yielded five RCTs, including 567 women. Calcium supplementation had started at 36 weeks of gestation in one study, and after delivery in the remaining four studies. The conclusion was that calcium supplementation seems not to be useful for improving maternal BMD during lactation. The studies were very heterogeneous in terms of dietary calcium intake, calcium dosage, and combination with vitamin D. Thus, the quality of evidence was low. The focus of their review did not match with the focus of our analysis, making any comparisons with our results impossible.

Earlier reviews on maternal calcium supplementation during pregnancy on offspring BMD or dental health were not available.

Conclusions

Implications for practice

We did not find any evidence of benefit of calcium supplementation during pregnancy without or with vitamin D on maternal or offspring bone density after delivery, or later during breastfeeding. Some long-term adverse effects in maternal bone firmness and growth of female offspring are even suspected. The only positive finding of high-dose calcium supplementation was a possible long-term benefit on offspring teeth firmness.

Our ability to draw firm conclusions on the impact of calcium on the studied outcomes is reduced by the few numbers of studies, low numbers of participants, and high amount of missing data in included studies. The included studies were also heterogeneous in terms of baseline dietary calcium intake, duration of pregnancy at start of intervention, duration of supplementation, calcium dosage, and combination with vitamin D. The quality of evidence is low, because of insufficient research data. Thus, the results should be interpreted with caution.

Implications for research

Data on the effects of calcium supplementation during pregnancy on maternal bone density during lactation are limited and the suspected harmful effects need to be either confirmed or refuted. If confirmed, the recovery of the adaptive mechanisms of calcium metabolism during pregnancy and after delivery needs to be studied further. Further research is also needed in order to establish whether calcium supplementation started during pregnancy and continued uninterrupted during lactation would be beneficial for maternal and offspring bone firmness.

Further research is also needed to provide evidence regarding long-term benefits or harms of the intervention on outcomes, such as maternal osteoporosis. In addition, more studies are needed on bone and dental health of infants and children of calcium-supplemented mothers.

Acknowledgments

The study was supported by the Children's Investment Fund Foundation UK (Grant 1910–04175). The authors wish to thank Juho Luoma and Juha Pääkkö for helping to plan the statistical analyses.

Author Contributions

K.T. participated in designing and writing the study protocol, screened the studies, and had primary responsibility in analyzing the data and writing the manuscript. P.K. participated in designing and writing the study protocol, screened the studies, and participated in analyzing the data and writing the manuscript. J.I. performed the literature searches and participated in writing the manuscript. R.O. participated in designing and writing the study protocol and revising the manuscript. U.A. participated in designing and writing the study protocol, interpreting the analyzed data, and writing the manuscript. P.A. participated in designing and writing the study protocol, interpreting the analyzed data, and writing the manuscript. O.T. participated in designing and writing the study protocol, interpreting the analyzed data, and writing the manuscript.

Peer review

The peer review history for this article is available at https://publons.com/publon/10.1111/nyas.14705

Supporting information

Additional supporting information may be found in the online version of this article.

Supplementary File 1. Search strategies used for the different literature databases.
Competing interests

The authors declare no competing interests.

References

1. Kovacs, C. 2016. Maternal mineral and bone metabolism during pregnancy, lactation and post-weaning recovery. Physiol. Rev. 96: 449–547.
2. Cormick, G., A.P. Betran, I.B. Romero, et al. 2019. Global inequities in dietary calcium intake during pregnancy: a systematic review and meta-analysis. BJOG 126: 444–456.
3. WHO. 2013. Calcium Supplementation During Pregnancy for the Prevention of Pre-Eclampsia and Its Complications. Geneva, Switzerland: World Health Organization.
4. Shamseer, L., D. Moher, M. Clarke, et al. 2015. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349: g7647.
5. 3.6.1 The Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE. In: Lefebvre C, J. Glanville, S. Briscoe, et al. 2014. 4.5.1 Technical supplement to Chapter 4: Searching for and selecting studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 6. J.P.T. Higgins, J. Thomas, J. Chandler, et al., Eds. Cochrane. Accessed September 6, 2020. https://training.cochrane.org/handbook/current/chapter-04-technical-supplement-searching-and-selecting-studies.
6. Glanville, J., G. Dooley, S. Wisniewski, et al. 2019. Development of a search filter to identify reports of controlled clinical trials within CINAHL Plus. Health Info Libr. J. 36: 73–90.
7. Sterne, J.A., J. Savovic, M.J. Page, et al. 2019. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366: i4898.
8. Cochrane Handbook for Systematic Reviews of Interventions Version 6. J.P.T. Higgins, J. Thomas, J. Chandler, et al., Eds. Cochrane. Accessed September 6, 2020. https://training.cochrane.org/handbook/current/chapter-04-technical-supplement-searching-and-selecting-studies.
9. Belizán, J.M., J. Villar, E. Bergel, et al. 1991. Calcium supplementation to prevent hypertensive disorders of pregnancy. N. Engl. J. Med. 325: 1399–1405.
10. Levine, R.J., J.C. Hauth, L.B. Curet, et al. 1997. Trial of calcium to prevent preeclampsia. N. Engl. J. Med. 337: 69–76.
11. Goldberg, G.R., L.M. Jarjou, T.J. Cole, et al. 2013. Randomized, placebo-controlled, calcium supplementation trial in pregnant Gambian women accustomed to a low calcium intake: effects on maternal blood pressure and infant growth. Am. J. Clin. Nutr. 98: 972–982.
12. Raman, L., K. Rajalakshmi, K.A. Krishnamachari, et al. 1978. Effect of calcium supplementation to undernourished mothers during pregnancy on the bone density of neonates. Am. J. Clin. Nutr. 31: 466–469.
13. Wang, Y.L., H. Wu, Y.B. Liu, et al. 1998. Newborn bone mineral density and health care during pregnancy. J. Bone Miner. Metab. 16: 190–192.
14. Diogenes, M.E., F.F. Bezerra, E.P. Rezende, et al. 2013. Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial. Am. J. Clin. Nutr. 98: 82–91.
15. Cullers, A., J.C. King, M. Van Loan, et al. 2019. Effect of prenatal calcium supplementation on bone during pregnancy and 1 y postpartum. Am. J Clin. Nutr. 109: 197–206.
16. Bergel, E., L. Gibbons, M.G. Rasines, et al. 2010. Maternal calcium supplementation during pregnancy and dental caries of children at 12 years of age: follow-up of a randomized controlled trial. Acta Obstet. Gynecol. Scand. 89: 1396–1402.
17. Koo, W.W., J.C. Walters, J. Estelritz, et al. 1999. Maternal calcium supplementation and fetal bone mineralization. Obstet. Gynecol. 94: 577–582.
18. Diogenes, M.E., F.F. Bezerra, E.P. Rezende, et al. 2015. Calcium plus vitamin D supplementation during the third trimester of pregnancy in adolescents accustomed to low calcium diets does not affect infant bone mass at early lactation in a randomized controlled trial. J. Nutr. 145: 1515–1523.
19. Jarjou, L.M., A. Prentice, Y. Sawo, et al. 2006. Randomized, placebo-controlled, calcium supplementation study in pregnant Gambian women: effects on breast-milk calcium concentrations and infant birth weight, growth, and bone mineral accretion in the first year of life. Am. J. Clin. Nutr. 83: 657–666.
20. Jarjou, L.M., M.A. Laskey, Y. Sawo, et al. 2010. Effect of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake. Am. J. Clin. Nutr. 92: 450–457.
21. Jarjou, L.M., Y. Sawo, G.R. Goldberg, et al. 2013. Unexpected long-term effects of calcium supplementation in pregnancy on maternal bone outcomes in women with a low calcium intake: a follow-up study. Am. J. Clin. Nutr. 98: 723–730.
22. Ward, K.A., L.M. Jarjou & A. Prentice. 2017. Long-term effects of maternal calcium supplementation on childhood growth differ between males and females in a population accustomed to a low calcium intake. Bone 103: 31–38.
23. Bupparasiri, P., P. Lumbiganon, J. Thinkhamrop, et al. 2015. Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes. Cochrane Database Syst. Rev. 2: CD007079.
24. Hofmeyr, G.J., T.A. Lawrie, Á.N. Atallah, et al. 2018. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. 1: CD001059.
25. Cai, G., J. Tian, T. Winzenberg, et al. 2020. Calcium supplementation for improving bone density in lactating women: a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 112: 48–56.
26. Page, M.J., J.E. McKenzie, P.M. Bossuyt, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372: n71.